

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA**

**Rivaroxaban for the treatment of acute symptomatic  
pulmonary embolism with or without symptomatic  
DVT and the prevention of recurrent VTE**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
---

As part of the consultation comments, when questioned about equality one of the consultees commented “Separate consideration of those patients unable to take warfarin”
---

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
---

Patients unable to take warfarin are not a protected group and therefore this is not considered an equality issue.
--

3. Has any change to the draft scope been agreed to highlight potential equality issues?
--

No
----

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

**Approved by Associate Director (name):** .....Janet Robertson...

**Date:** 15 November 2012